Gilead suspends access to experimental Covid-19 drug due to ‘overwhelming demand’
Gilead Sciences has temporarily stopped granting patients access to remdesivir, its experimental drug against the novel coronavirus that causes Covid-19, citing “overwhelming demand,” the company said Sunday.
The company said in a statement that it is focused on processing previously approved requests, and that it is developing a new system that it says will allow patients to get the drug in a similar timeframe to what it would have taken to work through the requests it has received.
